Member Info for Mars1

With that value on Promedior of $1.4bn it makes the broker valuation for NXP002 at $450m a little on the low side.

Always been the question which test have they been packing into standard NHS wrappers. If innova has already come in standard DHSC packaging, then it has to be a chosen U.K. test. I am of the opinion there will not just be one UK test as HMG want an industry to develop so more than one test will be used. So could ODX be packing visitect tests in own packaging and NHS packaging

Thought all the upscale work had been done, looks like further upscaling is planned
https://bidstats.uk/tenders/2021/W20/751239660

Life is all about the journey not so much about arriving however all countries where you arrive will have the tests they will accept, USA and Europe will have Mologic/Visitect listed as approvals/ independent verification already done/underway and other tests will not be accepted, place yer money take yer choice

Everyone knows what’s coming, 21/6 on Monday, it is only a matter of time. MHRA have set their parameters for LFTs to acceptable levels, should be a great weekend.

Get that feeling those selling at 59p now thing will have to pay more to get in. HMG out of contract on 21/6

MHRA not party to any contract they can stop the use of any item whether in stock or not

MHRA approval permits their use.

So they only have a max of 8 weeks stock left

Surely the extension is to use up existing stocks otherwise they have to be scrapped.

New app is available shows vaccinations and tests taken. Just applied for access. This is not the same as track and trace this is the passport version.

Meant to attach this
https://www.nhs.uk/conditions/prostate-cancer/should-i-have-psa-test/

This should be the next test developed by ODX, an antigen blood test to detect high levels of PSA. It affects 1 in 8 men and it should be an annual test for all over 50s which at present cannot be covered by current NHS resources. Prostat cancer is the largest problem and could be identified earlier and easier, come on ODX plan for the future

As far as I am aware this is the first time reference to NXP002 has appeared in a specialist journal on Fibrosis so another step forward, I am not sure sufferers of IPF have been aware of NFX.

Buys outrunning sells 5 to 1 and there is a red mist over the sp

It is for DHSC contract with no other party

Govts top up plan has just been blown out the water for Antigen tests (innova). The ODX contract was so they could do both Antibody and Antigen they were the only co in both consortiums. U.K. manufacturers are now going to have to step up further to fill the gap unless Govt goes further down the quality chain for lower performing tests where they basically started.

ODX attractive not only to any company wanting a listing but pretty much a free asset to anyone wanting to add another division as cash generation will be substantially higher than NAV by far

Meant to say this patent opens up NFX to a whole array of pharma in the US which were previously excluded

Not so sure this is a small tick in the right direction there are a large number of billion valued ‘small’ pharma in the US problem is it is cheaper to buy NFX than to deal for one drug